Filter results

Clinical Studies


  • “Prescribing” Exercise to Cancer Patients at Risk for Falls Rochester, Minn.

    The purpose of this study is to develop a data-driven approach that enables healthcare providers to “prescribe” exercise in the appropriate dose in a manner analogous to prescribing a drug.

  • A Qualitative Study of Mayo Clinic Calabresi Scholars and Former Scholars Rochester, Minn.

    To learn from scholars and former scholars of the Mayo Clinic Cancer Center’s “Paul Calabresi Clinical Oncology (K12) Training Program” in their own words what helped them and what did not help them from a career development standpoint.

  • Consent Forms in Cancer Research: Examining the Effect of Length on Readability Rochester, Minn.

    Consent forms for cancer clinical trials are getting longer and longer. This randomized trial uses mock consent forms to see if wordiness has any effect on patients' understanding and willingness to sign up for a cancer clinical trial.

  • Learning from Patients How They Were Educated on Chemotherapy Side Effects Rochester, Minn. To learn in patients’ own words how they were educated on chemotherapy side effects, what aspects of that education were most helpful, and what aspects could be done better (and why).
  • MC1512: A Randomized, Double-Blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Chemotherapy in Pancreas Cancer Patients Rochester, Minn.

    This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with gemcitabine hydrochloride in treating patients with a solid tumor that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and gemcitabine hydrochloride may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help gemcitabine hydrochloride work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet know whether giving gemcitabine hydrochloride with or without disulfiram is a better treatment for unresectable solid tumors or metastatic pancreatic cancer.

  • MC17C1 Double-Blinded, Placebo-Controlled Trial to Explore the Anti-Androgen, Ketoconazole, for Treating Patients with an Ongoing Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash (MC17C1) Rochester, Minn.

    This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash.

    We would like to see if use of topical ketoconazole will improve rashes in patients with EGFR inhibitor-induced rash.

Closed for Enrollment